Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PALI
SellSinkerPalisade Bio, Inc. · Healthcare · United States · $349M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Palisade Bio, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory and fibrotic diseases, with a lead candidate aimed at protecting the gastrointestinal tract. The company's competitive standing relies on the successful progression of its proprietary drug candidates through rigorous clinical trials and subsequent regulatory approval. As a development-stage firm, its valuation is heavily tied to its pipeline's potential.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0.3M | 0 | 0 | — | 0.5M | 0.4M | — | 12.6% |
| EPS | — | -0.57 | -0.13 | -0.17 | -0.30 | — | 0.65 | -0.23 | -0.28 | — |
| Shares | — | 173.6M | 173.6M | 173.6M | 159.6M | -8.0% | 174.3M | — | — | — |
| Debt | — | 0.4M | 0.4M | 0.2M | 71.0K | -44.0% | — | — | — | — |
| Equity | — | 12.5M | 11.3M | 7.5M | 129.4M | 118.1% | — | — | — | — |
| Op CF | — | -13.4M | -11.1M | -12.2M | -10.8M | — | -18.2M | — | — | — |
| Inv CF | -54.0K | -10.0K | -4.0K | 0 | — | — | — | — | — | — |
| Fin CF | — | 15.3M | 11.2M | 9.6M | 134.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PALI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PALI | Palisade Bio, Inc.(you) | $349M | 29 | Sell |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 31 | Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
| XFOR | X4 Pharmaceuticals, Inc. | $401M | 26 | Sell |
| PRTC.L | PureTech Health plc | $415M | 27 | Sell |
| CCCC | C4 Therapeutics, Inc. | $474M | 27 | Sell |
| PRLD | Prelude Therapeutics Incorporated | $437M | 25 | Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 32 | Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| ABEO | Abeona Therapeutics Inc. | $339M | 37 | Hold |
Peer medians: ROE -30.2% · P/E 27.1x · Gross margin 58.1%